A detailed history of Gsa Capital Partners LLP transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 133,800 shares of FOLD stock, worth $1.26 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
133,800
Previous 50,719 163.81%
Holding current value
$1.26 Million
Previous $503,000 184.1%
% of portfolio
0.11%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$9.55 - $12.09 $793,423 - $1 Million
83,081 Added 163.81%
133,800 $1.43 Million
Q2 2024

Aug 15, 2024

BUY
$9.04 - $11.75 $458,499 - $595,948
50,719 New
50,719 $503,000
Q4 2022

Feb 13, 2023

BUY
$9.89 - $12.7 $209,480 - $268,998
21,181 New
21,181 $259,000
Q2 2022

Aug 09, 2022

BUY
$6.23 - $11.12 $74,903 - $133,695
12,023 New
12,023 $129,000
Q4 2021

Feb 14, 2022

SELL
$9.82 - $12.44 $1.11 Million - $1.4 Million
-112,813 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$8.74 - $11.84 $985,985 - $1.34 Million
112,813 New
112,813 $1.08 Million
Q2 2021

Aug 05, 2021

SELL
$8.71 - $10.72 $488,430 - $601,145
-56,077 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$9.2 - $23.86 $515,908 - $1.34 Million
56,077 New
56,077 $554,000
Q4 2020

Feb 03, 2021

SELL
$13.47 - $24.89 $565,093 - $1.04 Million
-41,952 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$12.89 - $15.89 $540,761 - $666,617
41,952 New
41,952 $592,000
Q4 2019

Feb 12, 2020

SELL
$7.48 - $10.75 $100,007 - $143,727
-13,370 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$8.02 - $13.25 $107,227 - $177,152
13,370 New
13,370 $107,000
Q4 2017

Feb 14, 2018

SELL
$12.51 - $16.24 $256,530 - $333,017
-20,506 Closed
0 $0
Q3 2017

Nov 20, 2017

BUY
$11.74 - $15.78 $240,740 - $323,584
20,506
20,506 $309,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.64B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.